巴克莱集团宣布首次覆盖生物制药公司First Tracks Biotherapeutics,并给予"增持"评级。该机构同时设定了40美元的目标股价,显示出对该公司未来发展潜力的积极展望。
巴克莱集团宣布首次覆盖生物制药公司First Tracks Biotherapeutics,并给予"增持"评级。该机构同时设定了40美元的目标股价,显示出对该公司未来发展潜力的积极展望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.